Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

What we can learn from registry data to improve lipid goal attainment
What we can learn from registry data to improve lipid goal attainment
Hyperlipidemia
What we can learn from registry data to improve lipid goal attainment
- Kausik Ray, MBChB, MD, MPhil
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
AHA 2024
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Effect of decision support system on early optimization of lipid-lowering therapy
Effect of decision support system on early optimization of lipid-lowering therapy
AHA 2024
Effect of decision support system on early optimization of lipid-lowering therapy
- Kausik Ray, MBChB, MD, MPhil
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
MinuteCE®
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
0.75 program credits
- Ulrich Laufs, MD, PhD
0.75 program credits